<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705519</url>
  </required_header>
  <id_info>
    <org_study_id>CGOG3006/NEC-BEVAX</org_study_id>
    <nct_id>NCT04705519</nct_id>
  </id_info>
  <brief_title>Nab-paclitaxel Combined With Bevacizumab in the Treatment of Metastatic Neuroendocrine Carcinoma</brief_title>
  <official_title>A Prospective, Non-randomized, Multicenter, Phase II Study of Nab-paclitaxel Combined With Bevacizumab for Unresectable Recurrent or Metastatic Neuroendocrine Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Qilu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, phase II study evaluating efficacy and safety of Nab-paclitaxel&#xD;
      Combined With Bevacizumab for unresectable Recurrent or metastatic neuroendocrine carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nab-paclitaxel Combined With Bevacizumab will be evaluated in participants who have had ≥ 1&#xD;
      line of previous treatment. The primary endpoint is the Overall Survival (OS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2021</start_date>
  <completion_date type="Anticipated">January 5, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 5, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>an expected average of 24 months</time_frame>
    <description>Duration from the date of initial treatment to the date of death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>Percentage of patients who achieve partial response (PR) or complete response (CR) based on Response Evaluation Criteria In Solid Tumors (RECIST v1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>The percentage of patients who achieve complete remission(CR) or partial remission (PR) or stable disease(SD) determined by the RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>an expected average of 24 months</time_frame>
    <description>A duration from the date of initial treatment to radiographic disease progression or death of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>Proportion of objective complete response, partial response and stable patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>an expected average of 24 months</time_frame>
    <description>Including other occasional or rare AEs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neuroendocrine Carcinoma</condition>
  <arm_group>
    <arm_group_label>Nab-paclitaxel Combined With Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel, Bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel Combined With Bevacizumab</intervention_name>
    <description>Nab-paclitaxel 150mg/m2 ，iv drip, d1, Bevacizumab 5mg/kg, iv drip, d1, q2w.</description>
    <arm_group_label>Nab-paclitaxel Combined With Bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who provided written informed consent to be subjects in this trial&#xD;
&#xD;
          2. Aged ≥18 years&#xD;
&#xD;
          3. Has histologically-confirmed diagnosis of locally advanced unresectable or metastatic&#xD;
             neuroendocrine carcinoma&#xD;
&#xD;
          4. Has received and progressed on ≥1 prior systemic therapy for their advanced disease.&#xD;
&#xD;
          5. Performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
             Performance Scale&#xD;
&#xD;
          6. Have measurable disease as defined by RECIST 1.1 as determined by investigator&#xD;
             assessment&#xD;
&#xD;
          7. Agree to provide tumor tissue sample deemed adequate for histopathology confirmation&#xD;
&#xD;
          8. Adequate Organ Function Laboratory Values:&#xD;
&#xD;
             Hemoglobin ≥90g/L; Absolute neutrophil count (ANC) ≥1.5×109/L; Platelets ≥80×109/L;&#xD;
             AST and ALT ≤ 1.5 ULN or ≤ 3 ULN for subjects with liver metastases; Total bilirubin&#xD;
             ≤1.5 ULN; Serum creatinine ≤1.5 ULN or measured or calculated creatinine clearance &gt;&#xD;
             50ml/min; Albumin ≥ 30g/L;&#xD;
&#xD;
          9. Female subjects of childbearing potential must have a negative urine or serum&#xD;
             pregnancy test within 7 days prior to receiving the first dose of study medication and&#xD;
             must be willing to use an adequate method of contraception for the course of the study&#xD;
             through 90 days after the last dose of study medication. Male subjects of childbearing&#xD;
             potential must agree to use an adequate method of contraception starting with the&#xD;
             first dose of study therapy through 90 days after the last dose of study therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients have recovered adverse events associated with pretreatment to Grade 1 or&#xD;
             lower with CTCAE v5.0 excluding alopecia&#xD;
&#xD;
          2. Patients have an active malignancy (except for definitively treated basal cell&#xD;
             carcinoma of the skin, or carcinoma-in-situ of the cervix) within the past 5 years&#xD;
&#xD;
          3. Patients with uncontrolled central nervous system metastasis&#xD;
&#xD;
          4. Received anti-tumor therapy within 4 weeks, including: chemotherapy (the washout&#xD;
             period of oral fluorouracil drugs is 2 weeks), targeted therapy (the washout period of&#xD;
             small molecule targeted drugs is 2 weeks or 5 half-lives, whichever is shorter),&#xD;
             immunotherapy, etc.;&#xD;
&#xD;
          5. Received radical radiotherapy (including &gt;25% bone marrow radiotherapy) and brain&#xD;
             radiotherapy within 4 weeks; brachytherapy (such as implantation of radioactive&#xD;
             particles) within 60 days; received palliative radiotherapy for bone metastases within&#xD;
             1 week;&#xD;
&#xD;
          6. Patients with a history of prior treatment with docetaxel, paclitaxel, nab-paclitaxel&#xD;
             or bevacizumab&#xD;
&#xD;
          7. Received surgery within 4 weeks or unhealed wounds, Ulcers, fractures;&#xD;
&#xD;
          8. Uncontrollable malignant pleural effusion, ascites, or pericardial effusion (defined&#xD;
             as the investigator's judgment cannot be effectively controlled by diuretics or&#xD;
             puncture);&#xD;
&#xD;
          9. Patients have gastrointestinal diseases such as active gastric and duodenal ulcers,&#xD;
             ulcerative colitis, or active bleeding from unresected tumors, or other conditions&#xD;
             judged that may cause gastrointestinal bleeding or perforation;&#xD;
&#xD;
         10. Patients with evidence or medical history of thrombosis or obvious bleeding tendency&#xD;
             within 2 months (bleeding&gt; 30 mL within 2 months, hematemesis, melena, blood in the&#xD;
             stool), hemoptysis (&gt; 5 mL of fresh blood within 4 weeks);&#xD;
&#xD;
         11. Patients have arterial thrombosis or deep vein thrombosis occurred within 6 months; or&#xD;
             stroke and/or transient ischemic attack occurred within 12 months;&#xD;
&#xD;
         12. Active heart disease that is not well controlled, e.g. symptomatic coronary heart&#xD;
             disease, New York Heart Association (NYHA) congestive heart failure of grade II or&#xD;
             above, severe arrhythmias requiring drug intervention, myocardial infarction within&#xD;
             the past 6 months, LVEF&lt;50%&#xD;
&#xD;
         13. Patients judged with clinically significant electrolyte abnormalities&#xD;
&#xD;
         14. Patients have an active infection or an unexplained fever (temperature&gt; 38.5℃) during&#xD;
             the screening period or before the first administration&#xD;
&#xD;
         15. Patients with active tuberculosis (TB) who are receiving anti-tuberculosis treatment&#xD;
             or have received anti-tuberculosis treatment within 1 year&#xD;
&#xD;
         16. Is pregnant or breastfeeding&#xD;
&#xD;
         17. Patients were judged unsuitable as subjects of this trial by investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lin Shen, Professor</last_name>
    <phone>86-10-88196561</phone>
    <email>linshenpku@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen</last_name>
      <phone>86-10-88196561</phone>
      <email>linshenpku@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>January 9, 2021</last_update_submitted>
  <last_update_submitted_qc>January 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

